muscarinic antagonist


Also found in: Wikipedia.

mus·ca·rin·ic an·tag·o·nist

drugs that bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine.
Mentioned in ?
References in periodicals archive ?
The US Food and Drug Administration has accepted for review the new drug application for revefenacin (TD-4208), an investigational long-acting muscarinic antagonist, recently submitted by Dublin, Ireland-based biopharmaceutical company Theravance Biopharma, Inc.
The companies said revefenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA).
g, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.
The closed triple combination therapy consists of three medicines: fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, a long-acting muscarinic antagonist (LAMA); and vilanterol, a long-acting beta-adrenergic agonist (LABA).
AstraZeneca owns the development and commercial rights in the US and Canada to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease, and to Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD, in the US.
Since, there was no notable reduction in the contractile response to [alpha]-hederin after pretreatment with atropine (non-selective muscarinic antagonist), any specific muscarinic antagonist was employed in further study of [alpha]-hederin mode of action.
The long-acting muscarinic antagonist (LAMA)/LABA programme is in Phase III development in COPD.
Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
These effects were completely antagonized by the muscarinic antagonist ethylbenztropine, suggesting involvement of the muscarinic cholinergic receptors in baroreflex-mediated adjustments of the heart rate (8).
69) A more selective muscarinic antagonist, which inhibits myopia but does not affect these other ocular functions, would provide a more attractive treatment for the inhibition of myopia development.